Interestingly, effectors of MAP4K4 have been proposed as therapeutic targets in cardiovascular disease and neuronal injury: at least in preclinical studies, inhibiting TAK1/MAP3K7 is protective in ischemic stroke (White et al., 2012). This evidence concerns the gene MAP3K7 and cardiovascular disorder.